ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.

Area of Science:

• Pharmacogenomics
• Oncology
• Molecular Biology

Background:

• Platinum-based chemotherapy is standard for lung cancer.
• Identifying genetic markers for drug toxicity can improve treatment outcomes.
• Single nucleotide polymorphisms (SNPs) in platinum transport/detoxification genes may explain toxicity.

Purpose of the Study:

• To evaluate the role of three SNPs in predicting adverse events in lung cancer patients receiving platinum chemotherapy.
• To investigate the association between ABCB1, ABCC2, and GSTP1 gene polymorphisms and platinum-induced toxicities.

Main Methods:

• Genotyping of 82 lung cancer patients using real-time PCR for ABCB1 c.3435C>T, ABCC2 -24C>T, and GSTP1 c.313A>G SNPs.
• Correlation of patient genotypes with hematological, gastrointestinal, and renal toxicities (CTCAE v4.03).
• Multivariate analysis to confirm independent predictive value of SNPs.

Main Results:

• The ABCB1 c.3435C>T polymorphism was associated with a reduced risk of hematological toxicity (OR=0.20; p=0.01) for heterozygous CT carriers.
• A protective effect of the T allele was observed in dominant genetic models.
• No significant associations were found for ABCC2 or GSTP1 SNPs with observed toxicities.

Conclusions:

• The ABCB1 c.3435C>T polymorphism influences platinum-induced toxicity in lung cancer patients.
• The T allele of ABCB1 c.3435C>T may offer a protective effect against adverse events.
• Further research, including epigenetic studies, is warranted to validate this association.